Gendel develops a proprietary platform technology for the localized delivery of biological molecules to target sites within the body.
Industries BiotechnologyHeadquarters Regions Europe, Middle East, and Africa (EMEA) Closed Date May 9, 2012 Founded Date 1998 Founders Les Russell Operating Status Closed Last Funding Type Venture - Series Unknown Also Known As Genedel Ltd.
Company Type For Profit
Gendel has developed a unique, proprietary platform technology for the localised delivery of biological molecules to target sites within the body. Biopharmaceuticals may be loaded into the body's own natural carrier system by a physical process and released at the target site in response to the application of non-invasive, low intensity
ultrasound. Gendel's technology may be employed for the delivery of a range of biological payloads including antibodies, enzymes, peptides, olionucleotides and DNA as well as carrier peptides and gene therapy vectors.